Evotec AG Announces First Nine-Month Results and Corporate Update

[junkie-button url=”https://infomeddnews.com” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

STRONG OPERATIONAL AND FINANCIAL PERFORMANCE

EXPANSION OF LEADING EXTERNAL INNOVATION PLATFORM THROUGH ACQUISITION OF APTUIT

IMPORTANT MILESTONE ACHIEVEMENTS AND NEW WAYS OF ACCELERATING INNOVATION

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809)today reported financial results and corporate updates for the first nine months of 2017.

FINANCIAL PERFORMANCE REFLECTS GROWTH PATH

Group revenues: 42% increase to € 170.9 m (9M 2016: € 120.6 m);

EVT Execute revenues up 30% to € 165.1 m (9M 2016: € 126.6 m);

EVT Innovate revenues up 84% to € 33.2 m (9M 2016: € 17.9 m)

}  Adjusted Group EBITDA up 28% to € 39.3 m (9M 2016: € 30.6 m);

Adjusted EBITDA for EVT Execute of € 41.7 m (9M 2016: € 41.3 m);

Adjusted EBITDA for EVT Innovate of € (2.4) m (9M 2016: € (10.7) m)

}  R&D expenses at € 12.5 m (9M 2016: € 12.8 m)

}  Strong strategic liquidity position of € 88.8 m (after completion of Aptuit acquisition)

EVT EXECUTE – EXPANSION AND GROWTH OF HIGH-QUALITY SERVICES

}  Extension of value chain and high-quality development services following Aptuit acquisition

}  Cyprotex integration and performance proceeding according to plan

}  Multiple new and extended integrated drug discovery alliances, e.g. with Abivax, Blackthorn Therapeutics, Dermira, STORM Therapeutics and Tesaro (after period-end)

}  Significant progress within ongoing alliances (e.g. Bayer alliance in endometriosis: Start of second clinical Phase I study)

}  Indication extension and initiation of pre-clinical development of existing clinical asset with Bayer in new product franchise (undisclosed)

 

EVT INNOVATE – VERY GOOD SCIENTIFIC PROGRESS AND IMPORTANT MILESTONES

}  Important milestone achievements (Kidney disease alliance with Bayer, iPSC neurodegeneration alliance with Celgene, iPSC diabetes alliance with Sanofi)

}  Strong focus on expansion of iPSC platform through new strategic collaborations with Censo Biotechnologies, Fraunhofer IME-SP and Ncardia

}  Unique biobank approach through NURTuRE consortium in kidney diseases

}  Evotec joins NEPLEX consortium to accelerate the discovery of a novel drug discovery device to test drug candidates in human kidneys (after period-end)

}  Expansion of joint venture and strategic investment in Exscientia

}  Expansion of CKD Bayer alliance

}  Academic BRIDGE model gaining momentum: First North American BRIDGE established with MaRS Innovation in Canada (LAB150); two funding rounds completed in LAB282 projects (Oxford University)

CORPORATE

}  Acquisition of Aptuit: $ 300 m in cash (effective 11 August 2017)

}  Continued high-value strategic investments and company formations (e.g. Eternygen, Exscientia, Facio Therapies, Forge Therapeutics)

}  Loan facility issued by European Investment Bank of up to € 75 m to support Innovate R&D strategy

}  Novo Holdings A/S new strategic investor in Evotec holding >10%

 

GUIDANCE 2017 CONFIRMED

}  All elements of the financial guidance confirmed

 

 

For more information , please find attached the full text of our press release or

visit our Website: http://www.evotec.com

 

Webcast/Conference Call

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Conference call details

Date:                     Wednesday, 08 November 2017

Time:                    02.00 pm CET (01.00 pm GMT/08.00 am EST)

 

From Germany:                +49 69 22 22 29 043

From France:                    +33 170 750 705

From Italy:                         +39 02 3601 3806

From UK:                            +44 20 3009 2452

From USA:                         +1 855 402 7766

Access Code:                      37969784#

A simultaneous slide presentation for participants dialling in via phoneis available at http://www.audio-webcast.com/, password: evotec1117.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 22 22 33 985 (Germany) or +44 20 3426 2807 (UK) and in the USA by dialling +1 866 535 8030. The access code is 654573#. The on-demand version of the webcast will be available on our website:https://www.evotec.com/article/en/Investors/Finance/Financial-Reports-2015-2017/188/6/26.